Other findings from the clinical trial include: 54.6% of participants lost 10% of their starting body weight 36% of participants lost 15% of their starting body weight 18% of participants lost 18% of their starting body weight Orforglipron and maintenance dosing post weight loss injections One of the biggest challenges with injectable weight loss medications like tirzepatide (Mounjaro) and semaglutide (Wegovy) isn't losing the weight - it's keeping it off when you stop
Endogenous GLP-1 is involved in beta-amyloid protein-induced memory impairment and hippocampal neuronal death in rats
Despite the current dominance of injectables, patient preference for simpler oral formulations is growing, especially as a result of continuous international product launches
GLP-1 Receptor Agonist Market Key Takeaways The North America GLP-1 receptor agonistmarket accounted for a dominant share of 61.23% in 2025
High-fat, fried, and very rich foods are the most common triggers for nausea and gastrointestinal discomfort on GLP-1 medications because they slow gastric emptying further on top of the medication's effect
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
